ORIC Oric Pharmaceuticals
- 9.610
- +0.240+2.56%
- 9.610
- 0.0000.00%
Oric Pharmaceuticals News
Citi: Maintains ORIC Pharmaceuticals (ORIC.US) rating, adjusted from buy to buy rating, and adjusted the target price from $15.00 to $14.00.
ORIC Pharmaceuticals Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Buy Rating Affirmed for Oric Pharmaceuticals Amid Promising Clinical Data and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
ORIC Pharmaceuticals Analyst Ratings
Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts
ORIC Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
ORIC Pharmaceuticals Analyst Ratings
Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25
ORIC Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: DENTSPLY SIRONA (XRAY), Xenon (XENE) and Oric Pharmaceuticals (ORIC)
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating
ORIC Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Oric Pharmaceuticals Amid Positive Early-Stage Data and Strategic Development
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Xeris Pharmaceuticals (XERS)
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $15
Analysis
Price Target
No Data
